Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

by Sonesson, Christian, Johansson, Peter A., Johnsson, Eva, Gause-Nilsson, Ingrid
Published 2016

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

by Fioretto, Paola, Stefansson, Bergur V., Johnsson, Eva, Cain, Valerie A., Sjöström, C. David
Published 2016

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

by Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Published 2015

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

by Yavin, Yshai, Mansfield, Traci A., Ptaszynska, Agata, Johnsson, Kristina, Parikh, Shamik, Johnsson, Eva
Published 2016

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

by Fioretto, Paola, Mansfield, Traci A., Ptaszynska, Agata, Yavin, Yshai, Johnsson, Eva, Parikh, Shamik
Published 2016

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment per...

by Araki, Eiichi, Onishi, Yukiko, Asano, Michiko, Kim, Hyosung, Ekholm, Ella, Johnsson, Eva, Yajima, Toshitaka
Published 2016